Anti-Lyme Subunit Vaccines: Design and Development of Peptide-Based Vaccine Candidates.

Vaccinology today has been presented with several avenues to improve protection against infectious disease. The recent employment of the reverse vaccinology technique has changed the face of vaccine development against many pathogens， including Borrelia burgdorferi， the causative agent of Lyme disease. Using this technique， genomics and in silico analyses come together to identify potentially antigenic epitopes in a high-throughput fashion. The forward methodology of vaccine development was used previously to generate the only licensed human vaccine for Lyme disease， which is no longer on the market. Using reverse vaccinology to identify new antigens and isolate specific epitopes to protect against B. burgdorferi， subunit vaccines will be generated that lack reactogenic and nonspecific epitopes， yielding more effective vaccine candidates. Additionally， novel epitopes are being utilized and are presently in the commercialization pipeline both for B. burgdorferi and other spirochaetal pathogens. The versatility and methodology of the subunit protein vaccine are described as it pertains to Lyme disease from conception to performance evaluation.